Combining epigenetic drugs with PARP inhibitors for ovarian cancer treatment
Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer
This study is looking at how well combining certain cancer drugs can help women with ovarian cancer that doesn't respond to regular treatments, especially those with BRCA wild-type tumors, to see if this new approach can lead to better results.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11075402 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of combining poly ADP ribose polymerase inhibitors (PARPi) with various epigenetic drugs to improve treatment outcomes for patients with homologous recombination proficient ovarian cancer. The study focuses on patients whose cancer does not respond well to standard therapies, particularly those with BRCA wild-type tumors. By using a combination of drugs that target different pathways, the research aims to create a more effective treatment regimen. The approach involves preclinical models to identify the best drug combinations that can mimic the effects of BRCA mutations, potentially leading to better patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with homologous recombination proficient ovarian cancer, particularly those with BRCA wild-type tumors.
Not a fit: Patients with BRCA mutant ovarian cancer or those whose cancer is not homologous recombination proficient may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with hard-to-treat ovarian cancer, improving their chances of recovery.
How similar studies have performed: Other research has shown promising results with similar drug combination approaches, indicating potential for success in this novel application.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Khabele, Dineo — Washington University
- Study coordinator: Khabele, Dineo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.